Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors
- 775 Downloads
Few studies have evaluated the prevention of upper gastrointestinal complications (UGIC; bleeding or perforation) in patients with uncomplicated peptic ulcer (PU). We assessed the effect of proton pump inhibitors (PPI) in a non-randomized setting. To maximize exchangeability of exposed and unexposed groups we restricted the study to patients with a new diagnosis of PU, i.e., a clear indication. To minimize selection bias we mimicked an intention to treat approach by assessing the effect of PPI prescription after PU diagnosis.
Within a population of subjects aged 40–84 years from The Health Improvement Network database, 1997–2006, we identified 3,850 patients with incident PU. Among them, we confirmed 74 first UGIC episodes during a mean follow-up of 4 years. Exposure was prescription coverage during the month following PU diagnosis. We performed a nested case–control analysis and compared UGIC cases with 400 controls matched for age, sex, year and duration of follow-up. Relative risks (RR) and 95 % confidence intervals (CI) were estimated.
The overall incidence of UGIC was 4.6 cases/1,000 person-years; it was highest during the months after PU diagnosis, increased with age, and it was higher in men and subjects with Helicobacter pylori infection, anemia, and alcohol use at PU diagnosis. The RR for UGIC associated with PPI prescriptions during the month after PU diagnosis was 0.56 (95 % CI 0.31–1.0). The RR for NSAIDs with and without a PPI was 1.72 (0.68–4.45) and 3.27 (0.85–12.67), respectively.
Findings suggest that prescription of PPIs after a PU diagnosis is associated with a reduced risk of UGIC.
KeywordsPeptic ulcer Gastrointestinal complications Proton pump inhibitors Non-steroidal anti-inflammatory drugs Gastroprotection
The Pharmacoepidemiology Program at the Harvard School of Public Health and CEIFE are partially supported by training and research grants from various pharmaceutical companies, some of which manufacture non-steroidal anti-inflammatory drugs and/or gastroprotective agents. This study was funded by an unrestricted research grant from AstraZeneca R&D Mölndal, Sweden.
Conflict of interest
- 2.García Rodríguez L, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39.PubMedCrossRefGoogle Scholar
- 11.Walker AM. Observation and inference. An introduction to the methods of epidemiology. Newton Lower Falls: Epidemiology Resources Inc.; 1991.Google Scholar
- 17.NHS Terminology Service. http://www.connectingforhealth.nhs.uk/terminology/readcodes. 2006. Accessed 12 January 2013.
- 18.First Databank. MULTILEX for Primary Care. http://www.firstdatabank.co.uk/8/multilex-drug-data-file. 2010. Accessed March 2012.